Last reviewed · How we verify
Placebo to V260
V260 is an investigational vaccine candidate designed to elicit immune responses against a specific target antigen.
At a glance
| Generic name | Placebo to V260 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
V260 appears to be a vaccine in development by Merck Sharp & Dohme, though the specific antigen target and immunological mechanism are not publicly detailed in widely available sources. As a Phase 3 candidate, it has progressed beyond early-stage testing but the precise mechanism of action remains proprietary or insufficiently disclosed in public literature.
Approved indications
Common side effects
Key clinical trials
- CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults (PHASE1)
- CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults (PHASE1)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers (PHASE2)
- Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old (PHASE1)
- Optimising Rotavirus Vaccine in Aboriginal Children (PHASE4)
- Phase II Clinical Trial of the Inactivated Rotavirus Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to V260 CI brief — competitive landscape report
- Placebo to V260 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI